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1. DISEASE CHARACTERISTICS
==========================

1.1 Name of the disease (synonyms)
----------------------------------

Trimethylaminuria (fish odour syndrome, fish malodour syndrome, stale fish syndrome).

1.2 OMIM\# of the disease
-------------------------

602079\.

1.3 Name of the analysed genes or DNA/chromosome segments
---------------------------------------------------------

*FMO3*.

1.4 OMIM\# of the gene(s)
-------------------------

136132\.

1.5 Mutational spectrum
-----------------------

More than 30 sequence variants of the *FMO3* gene have been reported to cause trimethylaminuria. Most are missense variants, but nonsense variants, small (1- or 2- bp) deletions and one large (12.2- kb) deletion have been reported. Variant descriptions reported here are on the basis of the genomic reference sequence NG_012690.1 and the transcript reference sequence NM_001002294.2. Causative sequence variants are population specific. The most common identified to date are c.458C\>T (p.(Pro153Leu))^[@bib1]^ and c.913G\>T (p.(Glu305\*)),^[@bib2]^ in individuals of European ethnicity, and c.613C\>T (p.(Arg205Cys))^[@bib3]^ and c.1498C\>T (p.(Arg500\*)),^[@bib4]^ in Japanese. In one case, the haplotype in which a variant occurs is important: c.560T\>C (p.(Val187Ala)) has no effect on FMO3 activity, but when it occurs in *cis* with the common polymorphic variant c.472G\>A (p.(Glu158Lys)) it severely affects enzyme activity.^[@bib5]^ A human FMO3 database has been established^[@bib6]^ (<http://databases.lovd.nl/shared/genes/FMO3>) and causative sequence variants identified to date have been reported.^[@bib7],\ [@bib8],\ [@bib9]^ In addition to rare causative variants, 15 nonsynonymous single-nucleotide polymorphic (SNP) variants of *FMO3* have been identified.^[@bib10]^ Of these, only one, c.183C\>A (p.(Asn61Lys)), which occurs at low frequency, results in a severe reduction of enzyme activity.^[@bib11]^ However, some polymorphic variants, for example, c.472G\>A (p.(Glu158Lys)) and c.923A\>G (p.(Glu308Gly)), when present in *cis*, can cause a moderate decrease in enzyme activity.^[@bib10],[@bib12]^ When present in the homozygous state, they may cause mild or transient trimethylaminuria, particularly in infants and young children,^[@bib13],[@bib14]^ who have low expression of FMO3.^[@bib15]^ Two *FMO3* haplotypes that contain promoter-region SNP variants have been reported to severely reduce expression *in vitro*.^[@bib16]^ Although the impact of these haplotypes *in vivo* has not been validated, it is possible that they contribute to the disorder in the absence of coding-region variants. Four other haplotypes moderately reduce expression *in vitro*,^[@bib17]^ a consequence of the presence of a g.−5109G\>C SNP variant. Although none of the four haplotypes has a marked effect on the metabolism of trimethylamine (TMA) *in vivo*,^[@bib17]^ it is possible that they contribute to more moderate forms of the disorder.

1.6 Analytical methods
----------------------

The most common method is amplification of the eight coding exons,^[@bib18]^ by PCR with exon-specific primers, followed by DNA sequencing of the amplicons. Large deletions are rare, being identified in only one individual,^[@bib19]^ and can be identified by multiplex ligation-dependent probe amplification.

1.7 Analytical validation
-------------------------

Both strands of DNA should be sequenced. Identified sequence variants should be compared with databases and the literature to establish whether they correspond to known causative variants. If a novel variant is found, then it is important to establish that it abolishes or substantially reduces the ability of FMO3 to catalyse the *N*-oxygenation of trimethylamine, as assessed by assay of heterologously expressed variant protein.^[@bib1],[@bib20],[@bib21]^ If an individual is heterozygous for two different causative sequence variants, then analysis of the parents\' DNA will establish whether the variants are in *trans*. If an individual is homozygous or compound heterozygous^[@bib22]^ for loss-of-function variants of *FMO3*, then diagnosis is confirmed.

1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence\') or population prevalence)
----------------------------------------------------------------------------------------------------------

For severe, inherited trimethylaminuria, the incidence of heterozygous carriers in the white British population is 0.5--1.0%.^[@bib23]^ The frequency of the severe type of the disorder in this population could thus be as high as 1 in 40 000. The true prevalence of the disorder is unknown; however, of patients referred to a malodour clinic in Philadelphia, 35% had trimethylaminuria.^[@bib24]^

1.9 If applicable, prevalence in the ethnic group of the investigated person
----------------------------------------------------------------------------

The incidence of heterozygous carriers is higher in the other ethnic groups studied: 1.7% in Jordanian, 3.8% in Ecuadorian and 11.0% in New Guinean populations,^[@bib25]^ suggesting the frequency of the disorder may be as high as 1 in 3000 and 1 in 400 in the latter two groups, respectively.

1.10 Diagnostic setting
-----------------------
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Comment:

Trimethylaminuria usually presents with a body odour resembling that of rotten or decaying fish, the result of excess excretion of TMA in the breath, sweat, urine and reproductive fluids.^[@bib26],\ [@bib27],\ [@bib28],\ [@bib29]^ Individuals complaining of or exhibiting a fishy odour should be tested for urinary excretion of TMA, ideally on two separate occasions. Genetic testing should be offered to individuals who, under normal dietary conditions, excrete more than 10% of total TMA as the free amine. Molecular diagnosis can identify affected individuals and heterozygous carriers. It can also distinguish primary genetic trimethylaminuria (including severe presentations, caused by loss-of-function variants of *FMO3*, and milder presentations, commonly resulting from compound heterozygozity for milder missense variants and polymorphic variants that affect FMO3 activity) from other, less common forms of trimethylaminuria such as the following: An intermittent form, associated with menstruation,^[@bib30],[@bib31]^ probably related to decreased expression of *FMO3* in response to steroid hormones. The effect is more pronounced in women homozygous for combinations of polymorphic variants that affect FMO3 activity.^[@bib31]^A rare transient childhood presentation, as a consequence of immature *FMO3* expression, which is switched on after birth and increases with age;^[@bib15]^ young children who are heterozygous for a loss-of-function variant or have certain combinations of polymorphic variants of *FMO3* may exhibit mild symptoms of the disorder, which disappear with age.^[@bib13],[@bib14],[@bib32]^Unusually, as a consequence of viral hepatitis, liver disease, or a major transient overload of dietary precursors of TMA with the coexistence of function-altering polymorphic variants of *FMO3*.

Prenatal diagnosis is possible if the disease-causing variants in the family have been identified.

2. TEST CHARACTERISTICS
=======================
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2.1 Analytical sensitivity
--------------------------

(**proportion of positive tests if the genotype is present**)

It is estimated that 99% of coding-region *FMO3* variants may be detected by sequence analysis.

2.2 Analytical specificity
--------------------------

(**proportion of negative tests if the genotype is not present**)

Insufficient data to comment.

2.3 Clinical sensitivity
------------------------

**(proportion of positive tests if the disease is present)**

The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case.

Unknown. However, molecular genetic tests should distinguish between variants that abolish or severely affect FMO3 activity and, thus, cause severe primary trimethylaminuria, from those that have a relatively moderate effect, resulting in mild or transient forms of the disorder. But acquired and secondary forms of trimethylaminuria, which are not caused by sequence variants, would not give a positive genetic test.

Genotype analysis of 78 Japanese who tested positive for trimethylaminuria by urinary analysis revealed that 10 of the 13 diagnosed as severe were homozygous or compound heterozygous for known causative sequence variants.^[@bib17]^ Given the severity of their phenotypes, it is likely that the other three, who had no coding-region causative variants, have unidentified variants elsewhere in the *FMO3* gene that severely affect transcription or RNA processing. Of the 65 individuals classified as moderate or mild cases, none was homozygous or compound heterozygous for causative variants and, thus, suffer from secondary forms of the disorder.^[@bib17]^ Most of the moderate or mild cases were not a consequence of TMA overload but of a compromised ability to metabolize TMA to TMA *N*-oxide,^[@bib17]^ possibly due to the presence of unidentified sequence variants that have moderate effects on transcription or RNA processing, or due to inhibition of FMO3 activity, for instance, by posttranslational modification via nitric oxide-mediated *S*-nitrosylation.^[@bib33]^

2.4 Clinical specificity
------------------------

(**proportion of negative tests if the disease is not present**)

The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.

Only individuals who have tested positive for trimethylaminuria by urinary analysis, or their relatives, will be genetically tested.

2.5 Positive clinical predictive value
--------------------------------------

(**life-time risk to develop the disease if the test is positive**)

All those identified as homozygous or compound heterozygous for sequence variants that abolish or severely impair FMO3 activity suffer from the primary genetic form of the disorder and display symptoms of severe trimethylaminuria.

2.6 Negative clinical predictive value
--------------------------------------

(**probability not to develop the disease if the test is negative**)

Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.

Index case in that family had been tested:

Close to 100% if known causative sequence variants have been identified in the index patient.

Index case in that family had not been tested:

Unknown. Only patients that present with symptoms are analysed.

3. CLINICAL UTILITY
===================

3.1 (Differential) diagnostics: The tested person is clinically affected
------------------------------------------------------------------------

(To be answered if in 1.10 'A\' was marked)

### 3.1.1 Can a diagnosis be made other than through a genetic test?
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### 3.1.2 Describe the burden of alternative diagnostic methods to the patient

Very low. However, one individual developed an adverse reaction, with fever and vomiting, after a choline challenge.^[@bib39]^

### 3.1.3 How is the cost effectiveness of alternative diagnostic methods to be judged?

The initial diagnosis of trimethylaminuria is usually biochemical. Genetic testing will help to confirm the diagnosis, distinguish the various genetic and non-genetic forms of the disorder and identify asymptomatic heterozygous carriers.

### 3.1.4 Will disease management be influenced by the result of a genetic test?
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3.2 Predictive setting: the tested person is clinically unaffected but carries an increased risk based on family history
------------------------------------------------------------------------------------------------------------------------

(To be answered if in 1.10 'B\' was marked)

### 3.2.1 Will the result of a genetic test influence lifestyle and prevention?

If the test result is **positive** (please describe):

Not applicable.

If the test result is **negative** (please describe):

Not applicable.

### 3.2.2 Which options in view of lifestyle and prevention does a person at-risk have if no genetic test has been done (please describe)?

Not applicable.

3.3 Genetic risk assessment in family members of a diseased person
------------------------------------------------------------------

(To be answered if in 1.10 'C\' was marked)

### 3.3.1 Does the result of a genetic test resolve the genetic situation in that family?

A genetic test should distinguish primary inherited and secondary forms of trimethylaminuria, mild and severe forms of the inherited disorder and identify heterozygous carriers.

### 3.3.2 Can a genetic test in the index patient save genetic or other tests in family members?

The parents and offspring of an individual affected by primary inherited trimethylaminuria will be obligate heterozygotes. Sibs of an affected individual would have to be genetically tested to establish whether they were affected, unaffected or a heterozygous carrier.

### 3.3.3 Does a positive genetic test result in the index patient enable a predictive test in a family member?

Not applicable.

3.4 Prenatal diagnosis
----------------------

(To be answered if in 1.10 'D\' was marked)

### 3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnosis?

Yes, but it is not indicated.

4. IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
=================================================

Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe)

Affected individuals and their families benefit from counselling. Realization that the problem is the result of a recognized medical condition may help.

This work was supported by CIBERER, EuroGentest2 (unit 2: 'Genetic testing as part of health care\'), a Coordination Action under FP7 (grant agreement number 261469) and the European Society of Human Genetics.

The authors declare no conflict of interest.
